This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: B22.0 (HIV disease resulting in encephalopathy) | Special Copayment Reduction: V103 (severe intractable disease, 5 years) |
| B. Synonyms | HIV dementia; HIV encephalopathy; HIV-associated neurocognitive disorder (HAND); AIDS dementia complex (ADC); HIV-associated dementia (HAD) |
| C. Adult onset | Likelihood of adult onset: very high — HIV encephalopathy (HIV-associated neurocognitive disorder, HAND) occurs mainly in adults with intermediate to late-stage HIV infection. Before ART it occurred mainly at the AIDS stage (CD4 <200/μL), and even after ART, mild neurocognitive disorder (MND) can occur with a relatively preserved CD4 count. |
| 1. History | AIDS dementia complex (ADC) first described in 1986. HAND classification system proposed in 1991. HAD incidence decreased by 80% after ART in 1996, but mild HAND persists. HAND reclassified by the Frascati criteria in 2007. |
| 2. Causes | Direct involvement of the central nervous system (CNS) by HIV. HIV-infected monocytes/macrophages cross the blood–brain barrier (Trojan horse mechanism). Viral replication in the CNS and neuronal injury by neurotoxic viral proteins (gp120, Tat, Nef). |
| 3. Genetics | Not a hereditary disease. Host genes (CCR5 and CCR2 polymorphisms, CCL2, TNF-α, APOE ε4) influence susceptibility to HAND. HIV genotype (Tat and gp120 variants) determines the degree of neurotoxicity. |
| 4. General epidemiology | Incidence of HAD (severe HAND) before ART was about 15–30% of HIV patients. HAD decreased after ART, but the prevalence of mild to moderate HAND (ANI+MND) is about 40–50%. The risk of HAD is higher in untreated HIV patients. |
| 5. Pathophysiology | HIV-infected monocytes/macrophages infiltrate the CNS → infection of microglia → excitotoxicity by HIV Tat/gp120 → neuronal death. Neuroinflammation is the main mechanism of continued neuronal injury. |
| 6. Symptoms | Cognitive decline (impaired memory, concentration, and processing speed), behavioral changes (apathy, anxiety, depression), motor dysfunction (unsteady gait, hand tremor). With progression, dementia-level cognitive impairment, gait disturbance, and urinary incontinence. |
| 7. Signs | Abnormal neuropsychological testing; brain MRI: white matter changes, cortical atrophy, basal ganglia signal abnormalities. CSF: positive HIV RNA, elevated β2-microglobulin, pleocytosis (monocytes). Neurological abnormalities (hyperreflexia, spasticity). |
| 8. Screening | Neurocognitive screening is recommended for all HIV-infected individuals (HIV Dementia Scale, MoCA, or standard neuropsychological testing). Performed at initial diagnosis and when symptoms develop. |
| 9. Diagnosis | HAND classification based on the Frascati criteria (ANI, MND, HAD). Neuropsychological battery (five or more domains including attention, memory, processing speed, and executive function). Brain MRI, CSF examination, blood biomarkers (NfL, GFAP). |
| 10. Treatment | Early initiation and optimization of ART is the foundation of HAND prevention and treatment. Consider choosing ART with a high CNS penetration effectiveness (CPE) score. Cognitive rehabilitation, neuroprotective strategies (antioxidants, exercise). Symptomatic treatment (management of depression, anxiety, and parkinsonian symptoms). |
| 11. Prognosis | Before ART, median survival in HAD was 6 months. HAD has decreased greatly since ART. Mild HAND (ANI, MND) can persist even during ART. Prognosis improves with early ART initiation. Cognitive decline progresses faster in APOE ε4 carriers. |
| 12. Prevention | Suppress HIV viremia by early ART initiation. Choose an ART regimen with high CNS penetration effectiveness. Manage cardiovascular and metabolic risk factors (diabetes, hypertension, and dyslipidemia worsen HAND). Stop drug and alcohol abuse. |
| 13. References | Antinori A et al. Neurology 2007 and 9 others |
HIV encephalopathy was first described in 1986 as AIDS dementia complex (ADC). Price and Brew (1988) proposed a clinical staging system for ADC, defined as a distinctive neurological syndrome involving progressive impairment of cognitive, behavioral, and motor function. ADC occurred mainly at the AIDS stage before ART, and at that time was diagnosed in about 15–30% of HIV-infected individuals. In 1991 the American Academy of Neurology (AAN) first proposed a classification system for HIV-associated neurocognitive disorder (HAND).
After the introduction of HAART (highly active antiretroviral therapy) in 1996, the incidence of severe HAD fell by about 80%. However, a paradoxical pattern appeared in which mild and moderate HAND persisted or even increased. This is explained by the fact that even when viral replication is suppressed by ART, chronic inflammation in the CNS persists and a "viral reservoir" of HIV in the CNS is maintained. With the publication of the Frascati criteria in 2007, the current standard system was established, reclassifying HAND into three levels: asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND), and HIV-associated dementia (HAD).
Advances in cerebrospinal fluid (CSF) biomarker research, neuroimaging technology, and blood biomarkers of neuronal injury (NfL, GFAP, NFL, p-tau) have made early diagnosis and monitoring of the course of HAND possible. In the 2020s, residual HIV in the CNS, gut–brain axis dysbiosis, and accelerated aging have drawn attention as mechanisms by which HAND persists in patients on long-term ART.
The cause of HIV encephalopathy is direct involvement of the central nervous system (CNS) by HIV, which induces neuroinflammation and neuronal injury within the CNS.
HIV invades the CNS early in infection (within weeks of primary infection). Trojan horse mechanism: HIV-infected monocytes and T cells cross the blood–brain barrier (BBB) and bring HIV into the CNS. Thereafter, microglia and brain macrophages in the CNS become the main reservoir of HIV. HIV does not directly infect neurons (neurons, oligodendrocytes, astrocytes), but viral proteins (gp120, Tat, Vpr, Nef) and inflammatory mediators (TNF-α, IL-1β, IL-6, glutamate) released from infected microglia and macrophages indirectly damage neurons.
HIV gp120 binds to neurons through CXCR4 and CCR5, inducing apoptosis and causing excitotoxicity through calcium overload. The HIV Tat protein increases blood–brain barrier permeability and induces oxidative stress and mitochondrial dysfunction in neurons. Neuroinflammation resulting from chronic immune activation in the CNS is recognized as the key mechanism of continued neuronal injury.
HIV encephalopathy is not a hereditary disease. However, host gene polymorphisms and HIV viral genetics influence susceptibility to the development of HAND. CCR5 Δ32 mutation: homozygotes resist HIV-1 infection itself, reducing the risk of HAND. CCR2-64I polymorphism: CCR2 is involved in monocyte migration, and this variant has been reported to inhibit HIV entry into the brain and delay the development of HAD. CCL2 (MCP-1) gene polymorphism: CCL2 is a chemokine that attracts monocytes to the CNS, and a promoter polymorphism is associated with monocyte infiltration of the CNS and HAND severity. APOE ε4 allele: studies suggest that APOE ε4, a risk gene for Alzheimer's disease, accelerates neurocognitive decline in HIV-infected individuals. TNF-α promoter polymorphism: a high-TNF-α-producing phenotype raises the level of CNS inflammation and is associated with HAND severity. Clade-specific variation in the HIV Tat gene (especially clade B vs. clade C) may cause differences in the degree of neurotoxicity.
The overall prevalence of HAND remains high, at about 40–50% of HIV-infected individuals, even after ART. However, the prevalence of HAD (severe HAND) has fallen greatly from 15–30% before ART to about 2–8% after ART. A characteristic feature is that mild HAND (ANI+MND) remains high even after ART. Known risk factors include a low nadir CD4 count, untreated HIV, drug addiction, chronic hepatitis B and hepatitis C co-infection, increasing age, low educational level, and cardiovascular and metabolic risk factors (diabetes, hypertension). In Korea, systematic epidemiologic data on HIV-associated neurocognitive disorder are lacking, but in settings with good access to ART, mild HAND is presumed to be more common than HAD.
The pathogenesis of HAND is the combined action of direct CNS invasion by HIV and chronic neuroinflammation. In the early stage of HIV infection, HIV-infected monocytes and CD4+ T cells cross the blood–brain barrier (BBB) and bring HIV into the CNS. Microglia and perivascular macrophages in the CNS become the main reservoir of HIV. Infected microglia and macrophages continuously release HIV proteins (gp120, Tat, Vpr) and neurotoxic cytokines (TNF-α, IL-1β, IL-6, glutamate, nitric oxide), indirectly damaging neurons. Glutamate excess causes calcium influx through overactivation of NMDA receptors and mitochondrial dysfunction, resulting in neuronal death (apoptosis). HIV Tat directly impairs synaptic function and causes dopaminergic and serotonergic abnormalities, affecting cognitive, behavioral, and motor function. Even after ART, HIV in the CNS is not completely eliminated, so low-level viral replication and chronic neuroinflammation can persist. This is explained by the mechanisms of a "persistent CNS viral reservoir" and "chronic neuroinflammation."
HAND shows composite symptoms across three domains: cognitive, behavioral, and motor function. Cognitive decline: impaired short-term memory (frequently forgetting where objects were placed), poor concentration, reduced information processing speed, impaired executive function (planning, problem solving). Daily function is not greatly affected at first, but occupational and social function declines with progression. Behavioral symptoms: apathy, social withdrawal, depression, agitation, personality change. Psychotic symptoms (delusions, hallucinations) may appear in some. Motor dysfunction: unsteady and slowed gait, impaired fine motor function of the hands (difficulty writing or buttoning), lower limb spasticity. In advanced HAD, dementia-level global cognitive decline, gait ataxia, and bladder and bowel dysfunction appear.
On clinical examination, abnormal neurocognitive testing is key. Neurological examination may show lower limb hyperreflexia, abnormal plantar reflexes, bradykinesia, spasticity, and gait abnormalities. Brain MRI (T2/FLAIR) may show white matter signal abnormalities (periventricular white matter hyperintensity), cortical atrophy, and basal ganglia and thalamic signal abnormalities. CSF examination may show detection of HIV RNA (CSF viremia), elevated β2-microglobulin, mononuclear pleocytosis, and slightly elevated protein. Blood biomarkers of neuronal injury: elevated neurofilament light chain (NfL) is a sensitive indicator of CNS injury. Elevated GFAP (glial fibrillary acidic protein) has also been reported.
Neurocognitive screening is performed in all HIV-infected individuals at initial diagnosis and when symptoms change. As simple screening tools, the HIV Dementia Scale (HDS) (maximum 16 points; sensitivity 83% and specificity 94% at ≤10 points) and the Montreal Cognitive Assessment (MoCA) are used. If abnormalities are identified, a standard neuropsychological battery assessing five or more neurocognitive domains is performed. After ART initiation, improvement in cognitive function is followed at 6–12 month intervals. Because visual or hearing impairment, depression, sleep disorders, and drug adverse effects affect cognitive function, these are differentiated before assessment.
HAND is diagnosed according to the Frascati (2007) criteria. ① ANI (asymptomatic neurocognitive impairment): standardized score 1 SD or more below the mean in at least two cognitive domains, normal daily functioning. ② MND (mild neurocognitive disorder): 1 SD or more below in at least two cognitive domains, mild impairment of daily functioning. ③ HAD (HIV-associated dementia): 2 SD or more below in at least two cognitive domains, marked impairment of daily functioning. For diagnosis, standard neuropsychological testing (assessing five or more domains, including attention, processing speed, learning, recall, verbal fluency, visuospatial ability, and executive function) is performed. Brain MRI, CSF examination, and blood NfL measurement play an adjunctive role. Diagnosis is made after excluding other causes of neurocognitive disorder (opportunistic encephalitis, drug toxicity, depression, thyroid dysfunction, etc.).
The most important treatment of HAND is early initiation and optimization of ART. Suppressing blood HIV RNA to undetectable levels also reduces viral replication in the CNS. It has been suggested that drug combinations with a high CNS penetration effectiveness (CPE) score (for example, among dolutegravir/lamivudine/tenofovir AF combinations, dolutegravir has a high CPE) are advantageous for CNS viral suppression, but giving priority to CPE is not routinely recommended. If "CSF viral escape" is confirmed, in which the CSF viral load rises independently of the blood viral load while HAND progresses on ART, consider changing the ART regimen. Cognitive rehabilitation programs (cognitive training, occupational therapy) and regular aerobic exercise help maintain cognitive function in HAND patients. Drug treatment for depression and anxiety (SSRI, SNRI) and a trial of levodopa for parkinsonian motor symptoms may be useful for symptom relief.
Median survival of severe HAD patients before ART was about 6 months, but it has improved greatly since the introduction of ART. After ART initiation, cognitive function partially recovers in about 30–50% of HAD patients, but complete normalization is rare. At the ANI and MND stages, stabilization or some improvement is possible with ART optimization, but progression continues in some patients. HAND progressing even with suppressed blood viral load during ART ("HAND despite ART") is reported in about 20–30%, to which residual HIV in the CNS, chronic neuroinflammation, aging, and cardiovascular risk factors contribute in combination. Cognitive decline is reported to progress faster in HIV-infected individuals carrying APOE ε4. Early diagnosis, early ART, and management of comorbid risk factors improve long-term prognosis.
Early initiation and continuation of ART is the most effective way to prevent HAND. Suppressing HIV viremia early with ART minimizes the opportunity for HIV to invade the CNS. Management of cardiovascular and metabolic risk factors: diabetes, hypertension, and dyslipidemia independently cause CNS vascular damage and neurodegeneration, so manage them actively. Stopping drug and alcohol abuse: neurotoxic drugs and alcohol worsen HAND. Treatment of HCV co-infection: HCV can independently cause neurocognitive impairment, so treat early with DAAs. Evidence is accumulating that regular cognitive activity (reading, education, social participation) and aerobic exercise help prevent cognitive decline.
Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789-1799. DOI: 10.1212/01.WNL.0000287431.88658.8b. PMID: 17914061.
McArthur JC, Brew BJ, Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005;4(9):543-555. DOI: 10.1016/S1474-4422(05)70165-4. PMID: 16109361.
Heaton RK, Clifford DB, Franklin DR Jr, et al; CHARTER Group. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy. Neurology. 2010;75(23):2087-2096. DOI: 10.1212/WNL.0b013e318200d727. PMID: 21135382.
Price RW, Brew B, Sidtis J, Rosenblum M, Scheck AC, Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science. 1988;239(4840):586-592. DOI: 10.1126/science.3277272. PMID: 3277272.
Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras. J Neurovirol. 2004;10(6):350-357. DOI: 10.1080/13550280490521078. PMID: 15765807.
Bhaskaran K, Mussini C, Antinori A, et al. Changes in the incidence and predictors of HIV-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol. 2008;63(2):213-221. DOI: 10.1002/ana.21225. PMID: 18246521.
Everall IP, Hansen LA, Masliah E. The shifting patterns of HIV encephalitis neuropathology. Neurotox Res. 2005;8(1-2):51-61. DOI: 10.1007/BF03033819. PMID: 16260393.
Saylor D, Dickens AM, Sacktor N, et al. HIV-associated neurocognitive disorder — pathogenesis and prospects for treatment. Nat Rev Neurol. 2016;12(4):234-248. DOI: 10.1038/nrneurol.2016.27. PMID: 26965674.
Gelman BB. Neuropathology of HAND with suppressive antiretroviral therapy: encephalitis and neurodegeneration reconsidered. Curr HIV/AIDS Rep. 2015;12(2):272-279. DOI: 10.1007/s11904-015-0266-4. PMID: 25948536.
Valcour V, Paul R, Neuhaus J, Shikuma C; Hawaii Aging with HIV Cohort. The effects of age and HIV on neuropsychological performance. J Int Neuropsychol Soc. 2011;17(1):190-195. DOI: 10.1017/S1355617710001438. PMID: 21092375.